Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept
Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, today announced an extension of its Series A financing led by Flerie with support from new investors, InnovationQuarter Capital and Utrecht Health Seed Fund, and existing investor Thuja Capital.
